Published On: Wed, Oct 19th, 2016

Upgrades And Downgrades For Lannett Co Inc (NYSE:LCI)


Recently stock market analysts have updated their consensus ratings on shares of Lannett Co Inc (NYSE:LCI).

Most recent broker ratings

10/17/2016 – Lannett Co Inc had its “hold” rating reiterated by analysts at Deutsche Bank. They now have a USD 26 price target on the stock.

03/24/2016 – Lannett Co Inc was downgraded to “sell” by analysts at Canaccord Genuity. They now have a USD 18 price target on the stock.

02/04/2016 – Lannett Co Inc was upgraded to “buy” by analysts at Craig-Hallum. They now have a USD 38 price target on the stock.

12/29/2015 – Lannett Co Inc had its “hold” rating reiterated by analysts at Oppenheimer.

12/22/2015 – Lannett Co Inc had its “positive” rating reiterated by analysts at Susquehanna. They now have a USD 50 price target on the stock.

09/03/2015 – Lannett Co Inc had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 68 price target on the stock.

06/03/2015 – Raymond James began new coverage on Lannett Co Inc giving the company a “outperform” rating. They now have a USD 63 price target on the stock.

01/06/2015 – Lannett Co Inc was downgraded to “neutral” by analysts at Zacks. They now have a USD 51.9 price target on the stock.

03/04/2014 – Lannett Co Inc was upgraded to “overweight” by analysts at EVA Dimensions.

02/24/2014 – Lannett Co Inc was upgraded to “buy” by analysts at Thomson Reuters/Verus.

02/14/2014 – Lannett Co Inc was downgraded to “sell” by analysts at Jefferson Research.

02/10/2014 – Lannett Co Inc was upgraded to “buy” by analysts at TheStreet.

10/25/2013 – Bank of America Merrill Lynch began new coverage on Lannett Co Inc giving the company a “buy” rating.

10/04/2013 – Lannett Co Inc was downgraded to “hold” by analysts at Needham & Company.

Lannett Co Inc has a 50 day moving average of 29.08 and a 200 day moving average of 25.99. The stock’s market capitalization is 842.98M, it has a 52-week low of 16.91 and a 52-week high of 49.44.

The share price of the company (NYSE:LCI) was up +5.54% during the last trading session, with a high of 22.85 and the volume of Lannett Co Inc shares traded was 1541099.

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.